NCT05880472View on ClinicalTrials.gov

Percutaneous Holmium Injection in Pancreatic Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

April 22, 2025

Study Completion Date

April 22, 2025

Conditions
Pancreas Cancer
Interventions
DEVICE

Intratumoral

Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.

Trial Locations (1)

6525GA

Radboud University Medical Centre, Nijmegen

All Listed Sponsors
collaborator

Quirem Medical B.V.

INDUSTRY

collaborator

Terumo Medical Corporation

INDUSTRY

lead

Radboud University Medical Center

OTHER